US4388309A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for suppressing graft rejection in organ transplantation
Assignee: SHAKSVILLE Corp N V
•
Filing: 1981-06-10
•
Granted: 1983-06-14
•
Expires: 2001-06-10
Abstract
Abstract Suppression of the immunological rejection mechanism of a host which has received an organ transplant in achieved by the daily administration to the host of a ganglioside agent which effectively blocks the soluble immunological cell mediator interleukin 2 and /or a blastogenic factor. By binding to the mediator for T cell blast formation the mediator is prevented from binding to the asialo GM1 receptor on the surface of the T effector cell. Blastogenesis does not occur and the cell mediated rejection of the graft is prevented.
Inventors
- 👤 Hans-Ake Fabricius
- 👤 Eckart U. Kottgen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 11:52
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
58 words
A method for inhibiting cell mediated rejection of organ transplants from a donor to a host comprising administering to the host an immunologically suppressive effective amount of from about 0.5 μg to about 10 mg per kilogram body weight per day of a desialylated ganglioside capable of blocking soluble mediators needed for T cell blast formation and proliferation.
Claim 2
Independent Claim
58 words
A method for inhibiting cell mediated rejection of organ transplants from a donor to a host comprising administering to the host an immunologically suppressive effective amount of from about 0.5 μg to about 10 mg per kilogram body weight per day of a desialylated ganglioside capable of blocking soluble mediators needed for T cell blast formation and proliferation.
Claim 3
Dependent Claim
12 words
The method of claim 1 wherein the desialylated ganglioside is asialo GMl.
Claim 4
Dependent Claim
18 words
The method of claim 1 wherein the desialylated ganglioside is asialo GD 1a, GD 1b or GT 1.
Claim 5
Dependent Claim
25 words
The method of claim 1 wherein the organ transplant is a heart transplant, kidney transplant, liver transplant, pancreatic islet transplant or a bone marrow transplant.
Claim 6
Dependent Claim
39 words
The method of claim 1 wherein the ganglioside is administered to the host once or twice daily as an injectable solution of the ganglioside in an alcohol/water mixture having a ratio of alcohol to water of 0:100 to 1:100.
Claim 7
Dependent Claim
25 words
The method of claim 4 wherein the injectable solution comprises an aqueous solution of a complex of the ganglioside with a water soluble organic carrier.
Claim 8
Dependent Claim
25 words
The method of claim 5 wherein the organic carrier is selected from the group consisting of albumin, antibodies, lectins, glycoproteins, desoxyribonucleic acid, dextran and liposomes.
Claim 9
Dependent Claim
30 words
The method of claim 1 wherein the ganglioside is administered to the host starting during a period of from 0 to 48 hours after the host recieves the organ transplant.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-06-13 | 1986-12-13 | 1987-06-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-06-13 | 1990-12-13 | 1991-06-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-06-13 | 1994-12-13 | 1995-06-14 | $7700.00 | Window Closed / Lapsed |